Karen is a member of Broadway Angels and is launching QB3's Executive Mentorship program. Previously, Karen was the CEO of Redwood Bioscience which she joined as the first non-founder employee, leading the company through its successful acquisition by Catalent (CTLT). Redwood, now Catalent Biologics, continues to be a pioneer in developing therapeutic conjugate technology and antibody-drug conjugates for improving cancer treatment. Prior to joining Redwood, Karen co-founded and was a Partner with Thomas, McNerney & Partners, a health care technology-focused venture firm with $600 million under management. Previously, she was a General Partner of Coral Ventures and a member of Warburg Pincus LLC’s healthcare technology venture group. During her venture career, Karen was involved with 15 companies from initial investment that went public and/or were acquired; three of which she launched in collaboration with scientific founders. Karen began her career as a member of Alex. Brown & Sons’s health care and insurance corporate finance teams. She graduated Phi Beta Kappa and magna cum laude with a B.S. in Economics from the Wharton School at the University of Pennsylvania.